← Back to IPO List

Parabilis Medicines

Last updated: June 15, 2026
Ticker
PBLS
Exchange
NYSE
IPO Date
Pending
Price Range
$17.00 - $19.00
Deal Size
$670 million
View PBLS Live Chart on TradingViewAffiliate link — we may earn a commission.

Company Snapshot

Parabilis Medicines is a biotechnology company focused on developing innovative therapies for unmet medical needs. The company aims to leverage its proprietary technology platform to create novel treatments that improve patient outcomes. Their key value proposition lies in their ability to address complex diseases with targeted therapies.

Key Financials

Metric202420232022
RevenueNot providedNot providedNot provided
Adjusted Net IncomeNot providedNot providedNot provided

S-1 Highlights

Market & Competition

The biotechnology industry is highly competitive, with Parabilis Medicines competing against established players such as Amgen, Gilead Sciences, and Regeneron Pharmaceuticals.

Use of Proceeds

Proceeds from the IPO will be used to fund clinical trials, advance their research and development efforts, and support general corporate purposes.

Key Risk Factors

  • ●The company faces significant risks related to the successful development and commercialization of its drug candidates, which may not achieve regulatory approval.
  • ●Parabilis Medicines may encounter challenges in securing adequate funding to support its ongoing research and operational activities.

Reported Broker Availability

No broker information available yet

Check back later for updates

Reported by users or publicly disclosed. Information is for reference only.

Important Links & Filings

PBLS Live Chart on TradingView →SEC S-1 Filing →
Important: Information presented on this website is aggregated from publicly available sources and voluntary user submissions. It is provided for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. IPO access and availability may vary by broker and is not guaranteed; always verify details directly with your broker before making any investment decisions. We are not affiliated with, endorsed by, or acting on behalf of any broker-dealers, underwriters, or issuing companies. Some links to broker platforms may be affiliate links, and we may earn a commission if you open an account through those links. See full disclaimer for additional information.